Leap Therapeutics (LPTX) Competitors $0.30 -0.01 (-4.00%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$0.30 +0.00 (+0.20%) As of 05:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX vs. DTIL, AADI, FGEN, PEPG, EGRX, ANVS, ACRV, SCYX, RNXT, and OTLKShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Precision BioSciences (DTIL), Aadi Bioscience (AADI), FibroGen (FGEN), PepGen (PEPG), Eagle Pharmaceuticals (EGRX), Annovis Bio (ANVS), Acrivon Therapeutics (ACRV), SCYNEXIS (SCYX), RenovoRx (RNXT), and Oncobiologics (OTLK). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. Its Competitors Precision BioSciences Aadi Bioscience FibroGen PepGen Eagle Pharmaceuticals Annovis Bio Acrivon Therapeutics SCYNEXIS RenovoRx Oncobiologics Precision BioSciences (NASDAQ:DTIL) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do analysts rate DTIL or LPTX? Precision BioSciences presently has a consensus target price of $47.00, indicating a potential upside of 863.11%. Leap Therapeutics has a consensus target price of $3.38, indicating a potential upside of 1,042.52%. Given Leap Therapeutics' higher possible upside, analysts clearly believe Leap Therapeutics is more favorable than Precision BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, DTIL or LPTX? Precision BioSciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Do insiders and institutionals hold more shares of DTIL or LPTX? 38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 4.0% of Precision BioSciences shares are held by company insiders. Comparatively, 7.5% of Leap Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, DTIL or LPTX? Precision BioSciences has higher revenue and earnings than Leap Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$68.70M0.84$7.17M-$8.81-0.55Leap TherapeuticsN/AN/A-$67.56M-$1.58-0.19 Is DTIL or LPTX more profitable? Leap Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. Precision BioSciences' return on equity of -176.47% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences-6,205.79% -176.47% -69.05% Leap Therapeutics N/A -237.65%-155.38% Does the media prefer DTIL or LPTX? In the previous week, Precision BioSciences' average media sentiment score of 1.02 beat Leap Therapeutics' score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the media. Company Overall Sentiment Precision BioSciences Positive Leap Therapeutics Neutral SummaryPrecision BioSciences beats Leap Therapeutics on 9 of the 14 factors compared between the two stocks. Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.75M$3.16B$5.76B$10.50BDividend YieldN/A2.36%5.53%4.57%P/E Ratio-0.1921.0475.9626.62Price / SalesN/A252.06473.7891.77Price / CashN/A46.3537.4661.85Price / Book0.329.7813.486.45Net Income-$67.56M-$52.73M$3.29B$271.57M7 Day Performance-5.59%3.16%1.83%2.61%1 Month Performance-0.81%4.69%4.00%7.28%1 Year Performance-88.59%16.37%75.89%29.60% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics2.3171 of 5 stars$0.30-4.0%$3.38+1,042.5%-89.1%$12.75MN/A-0.1940Gap DownDTILPrecision BioSciences4.3043 of 5 stars$4.50-2.4%$47.00+944.4%-48.0%$54.34M$68.70M-0.51200AADIAadi BioscienceN/A$1.99-1.0%N/A-0.5%$49.15M$25.07M-0.8740FGENFibroGen4.235 of 5 stars$11.84-1.6%$43.00+263.2%+28.7%$48.65M$29.62M-31.16570PEPGPepGen2.5799 of 5 stars$1.59+7.4%$7.25+356.0%-78.3%$48.54MN/A-0.5430EGRXEagle Pharmaceuticals1.3758 of 5 stars$3.73+16.0%N/A-13.5%$48.38M$257.55M0.00100Gap DownANVSAnnovis Bio1.935 of 5 stars$2.42-2.6%$17.33+617.7%-72.2%$48.33MN/A-1.183ACRVAcrivon Therapeutics2.8325 of 5 stars$1.51-0.7%$15.50+926.5%-78.1%$47.81MN/A-0.6758SCYXSCYNEXIS0.5957 of 5 stars$1.10-1.8%N/A-27.7%$46.96M$3.75M-2.7560Positive NewsRNXTRenovoRx2.5636 of 5 stars$1.27-0.8%$7.50+490.6%+19.4%$46.91M$40K-3.346Gap UpHigh Trading VolumeOTLKOncobiologics2.0434 of 5 stars$1.05+1.0%$9.60+814.3%-82.6%$46.20MN/A-1.8420News CoverageNegative NewsAnalyst ForecastGap Down Related Companies and Tools Related Companies Precision BioSciences Alternatives Aadi Bioscience Alternatives FibroGen Alternatives PepGen Alternatives Eagle Pharmaceuticals Alternatives Annovis Bio Alternatives Acrivon Therapeutics Alternatives SCYNEXIS Alternatives RenovoRx Alternatives Oncobiologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPTX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LPTX Stock Alerts